Home » Stocks » AFIB

Acutus Medical, Inc. (AFIB)

Stock Price: $12.89 USD -0.58 (-4.31%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
After-hours: $13.90 +1.01 (7.84%) Apr 16, 6:25 PM
Market Cap 362.14M
Revenue (ttm) 8.46M
Net Income (ttm) -101.98M
Shares Out 27.85M
EPS (ttm) -8.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $12.89
Previous Close $13.47
Change ($) -0.58
Change (%) -4.31%
Day's Open 13.65
Day's Range 12.42 - 13.83
Day's Volume 176,787
52-Week Range 12.32 - 38.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

New York, New York--(Newsfile Corp. - March 31, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ: AFIB). Such investors ar...

2 weeks ago - Newsfile Corp

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and t...

2 weeks ago - GlobeNewsWire

NEW YORK, March 30, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ: AFIB).  Such investors are advised to c...

2 weeks ago - PRNewsWire

CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and t...

1 month ago - GlobeNewsWire

CARLSBAD, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and t...

1 month ago - GlobeNewsWire

Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System Contract Pricing Now Widely Available for the AcQMap® High Resolution 3D Imaging and Mapping System

1 month ago - GlobeNewsWire

CARLSBAD, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB) today announced the appointment of David Roman as the company's Chief Financial Officer, effective March 1, 2021. In add...

2 months ago - GlobeNewsWire

CARLSBAD, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and tr...

2 months ago - GlobeNewsWire

CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and tr...

3 months ago - GlobeNewsWire

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and tr...

3 months ago - GlobeNewsWire

About AFIB

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based i... [Read more...]

Industry
Medical Devices
IPO Date
Aug 6, 2020
Stock Exchange
NASDAQ
Ticker Symbol
AFIB
Full Company Profile

Financial Performance

In 2020, Acutus Medical's revenue was $8.46 million, an increase of 198.45% compared to the previous year's $2.84 million. Losses were -$101.98 million, 5.09% more than in 2019.

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for Acutus Medical stock is "Buy." The 12-month stock price forecast is 21.67, which is an increase of 68.11% from the latest price.

Price Target
$21.67
(68.11% upside)
Analyst Consensus: Buy